In line with our findings, Cheon and co-workers recently demonstrated for other KRAS mutant colorectal cancer cells a bypass mechanism of refametinib resistance to MEK inhibition involving the activation of STAT3 and MAPK triggered by MIF overexpression [53]. The gene discussed is MIF; the disease is colorectal cancer.